Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 02 2024 - 7:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage
company pioneering the use of gene therapy as a new standard of
care for highly prevalent ocular diseases, today announced that
Laurent Fischer, M.D., president and chief executive officer of
Adverum Biotechnologies, will participate in a fireside chat at the
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on
August 15, 2024 at 2:00 p.m. ET.
The webcast of the fireside chat may be accessed under Events
and Presentations in the Investors section of Adverum’s website. A
replay of the webcast will be available on the website for at least
30 days following the presentation.
About Adverum BiotechnologiesAdverum
Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that
aims to establish gene therapy as a new standard of care for highly
prevalent ocular diseases with the aspiration of developing
functional cures to restore vision and prevent blindness.
Leveraging the capabilities of its proprietary intravitreal (IVT)
platform, Adverum is developing durable, single-administration
therapies, designed to be delivered in physicians’ offices, to
eliminate the need for frequent ocular injections to treat these
diseases. Adverum is evaluating its novel gene therapy candidate,
ixoberogene soroparvovec (Ixo-vec, formerly referred to as
ADVM-022), as a one-time, IVT injection for patients with
neovascular or wet age-related macular degeneration. Additionally,
by overcoming the challenges associated with current treatment
paradigms for debilitating ocular diseases, Adverum aspires to
transform the standard of care, preserve vision, and create a
profound societal impact around the globe. For more information,
please visit www.adverum.com.
Inquiries: Adverum Investor
RelationsEmail: ir@adverum.com
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024